Molnupiravir

• CAT Number: I008442
• CAS Number: 2349386-89-4
• PubChem Substance ID: 145996610
• Molecular Formula: C13H19N3O7
• Molecular Weight: 329.31
• Purity: ≥95%
• Synonyms: EIDD-2801; EIDD 1931-isopropyl ester; Lagevrio; MK-4482; Molnupiravir; β-D-N4 hydroxycytidine-5′-isopropyl ester
• IUPAC Name: [(2R,3S,4R,5R)-3,4-dihydroxy-5-[4-(hydroxyamino)-2-oxopyrimidin-1-yl]oxolan-2-yl]methyl 2-methylpropanoate
• InChI: InChI=1S/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/m1/s1
• InChIKey: HTNPEHXGEKVIHG-QCNRFFRDSA-N
• SMILES: CC(C)C(=O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)NO)O)O

Molnupiravir（Cat No.:I008442）is an antiviral drug used in the treatment of COVID-19. It works by inhibiting the replication of the SARS-CoV-2 virus through its incorporation into viral RNA, leading to mutations that disrupt viral reproduction. Molnupiravir is administered orally and is particularly useful for patients at risk of developing severe COVID-19, such as those with underlying health conditions. The drug has been shown to reduce the risk of hospitalization and death in certain high-risk populations. It is part of ongoing efforts to combat viral infections with targeted, effective treatments.